BioSpace News Archive

The Board of Directors of Nordic Nanovector has on 29th of January 2018 decided to grant 216 550 Performance Share Units to employees in accordance with the authorisation granted at the Extraordinary General Meeting held on 20 December 2017.

The 100-patient study that appeared in the December 2017 ASJ demonstrated high patient satisfaction with Silhouette InstaLift for lifting of the mid-face while improving a number of age related changes.

This software medical device, based on deep learning technologies, automatically analyzes non-contrast head CT images.

Antibe announce that the final subjects have been enrolled and are on treatment in the key Phase 2B double-blind clinical trial of ATB-346.

Endo will announce its fourth-quarter 2017 financial results on February 27, 2018 and members of its senior management team will host a conference call and webcast before the U.S. financial markets open at 7:30 a.m. ET.

Advaxis announces that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations (C5) taking place March 23-27, 2018 at the Queen Elizabeth Fairmont in Montreal.

Emmaus Life Sciences announced today that it has a Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services allowing coverage of Endari (L-glutamine oral powder) to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

This label expansion is the first for electroCore since gammaCore received its initial FDA clearance.

Dr. Plotkin joins Ritter Pharmaceuticals with nearly thirty years of experience in strategic, global clinical pharmaceutical research involving all phases of drug development.

The trials will be anticipated to use a 3+3 design with 5mg/kg, 10mg/kg and 15mg/kg dosing regimens. O